Theriva Biologics reports Q2 EPS ($1.93) vs. ($10.72) last year

“We are highly encouraged by the progress we’ve made so far in the first half of 2025,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics (TOVX). “We have achieved a significant milestone with the positive readout from the Phase 2b VIRAGE trial, where our lead asset VCN-01 achieved its primary survival and safety endpoints in metastatic pancreatic cancer patients treated with first-line standard of care chemotherapy gemcitabine/nab-paclitaxel. We are now preparing a study protocol for a potential Phase 3 clinical trial and advancing VCN-01’s manufacturing scale-up using our propietary suspension cell line. Leveraging our clinical and manufacturing momentum, we have also initiated strategic outreach to identify potential partners for VCN-01’s late-stage clinical development.”